Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Windtree Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
WINT
Nasdaq
8731
https://windtreetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Windtree Therapeutics Inc
Windtree Therapeutics Announces Reverse Stock Split
- Apr 18th, 2024 12:00 pm
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
- Apr 17th, 2024 12:00 pm
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
- Apr 8th, 2024 8:48 pm
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
- Feb 1st, 2024 1:00 pm
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
- Jan 31st, 2024 1:00 pm
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
- Jan 26th, 2024 2:20 pm
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
- Jan 25th, 2024 1:30 pm
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
- Jan 18th, 2024 2:00 pm
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
- Jan 17th, 2024 1:00 pm
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
- Jan 2nd, 2024 9:05 pm
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
- Dec 19th, 2023 2:30 pm
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
- Dec 18th, 2023 1:00 pm
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
- Nov 16th, 2023 1:00 pm
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
- Nov 14th, 2023 1:55 pm
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
- Nov 9th, 2023 9:15 pm
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
- Nov 8th, 2023 1:00 pm
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
- Oct 12th, 2023 11:30 am
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
- Oct 10th, 2023 11:30 am
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
- Oct 3rd, 2023 12:00 pm
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Sep 21st, 2023 1:35 pm
Scroll